Vanda Pharmaceuticals Inc.

VNDANASDAQ • USD
ThemeBiotech - Drug Development›Neuroscience & CNS
5.35 USD
↘ 0.09 (1.65%)AT CLOSE (11:59 AM EDT)
5.34
↘ 0.01 (0.19%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
5.34
↘ 0.01 (0.19%)
🔴Market: CLOSED

Shares of Vanda Pharmaceuticals Inc. (VNDA) are trading at $5.34. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Aug 26, 2026.

Open?$5.43
High?$5.43
Low?$5.24
Prev. Close?$5.44
Volume?928.4K
Avg. Volume?972.5K
VWAP?$5.32
Rel. Volume?0.95x
Bid / Ask
Bid?$4.42 × 100
Ask?$6.10 × 100
Spread?$1.68
Midpoint?$5.26
Valuation & Ratios
Market Cap?328.9M
Shares Out?60.5M
Float?54.1M
Float %?89.5%
P/E Ratio?N/A
P/B Ratio?1.49
EPS?-$4.55
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Themes
Biotech - Drug Development›Neuroscience & CNSBiotech - Drug Development›Rare Disease Therapeutics
Employees
533
Market Cap
328.9M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.vandapharma.com
Listed
2006-04-12
Address
2200 PENNSYLVANIA AVE NW
WASHINGTON, DC 20037
Phone: 202-734-3400
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
23
Short Sent.?
54
Piotroski F-Score?1/9Weak
Altman Z-Score?-1.36Distress
Confidence?61%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?14.18%High
Short Interest?7.7M
Days to Cover?6.2
Free Float54.1M
Avg Daily Volume1.2M
Settlement Date2026-08-14
Financial Health
Current Ratio?1.61Adequate
Quick Ratio?1.60Adequate
Cash Ratio?0.34Low
Debt/Equity?0.01Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
87
1.49CHEAP▾
P/S?
Peers
100
S&P
78
1.52CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.6CHEAP▾
EV/Sales?
Peers
100
S&P
87
1.28CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-124.8%WEAK▾
ROA?
S&P
3
-66.6%WEAK▾
Cash Flow & Enterprise
FCF?$-143005000
Enterprise Value?$276.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist